Bristol Myers Squibb has disclosed its terms of use for the drug claims data that providers must give it in exchange for access to 340B pricing on BMS’s oral oncology drugs Revlimid, Pomalyst, and Thalomid.
BMS acquired the three drugs
…
Articles by : Tom Mirga, Editor at Large
340B hospitals and health centers say they have a lot of questions about new requests from Express Scripts (ESI) to verify 340B drug reimbursement claims in 10 business days.
Hospital and health center covered entities report getting one or more
…
The federal government on Monday accused a Tennessee health system of unlawfully paying a Memphis-area private oncology practice for patient referrals, letting the system “recoup a staggering discount in costs” through the 340B program. The 340B health system—Methodist Le Bonheur
…
The federal government, as expected, is challenging a federal district judge’s February opinion and March final orders in drug manufacturer AstraZeneca’s 340B contract pharmacy lawsuit.
The U.S. Justice Department (DOJ) announced the appeal in a one-sentence court filing on April
…
Today is the last day for hospitals that have lost their 340B eligibility due to the COVID-19 public health emergency to file paperwork to be reinstated to the drug discount program.
A federal spending bill signed on March 15 included
U.S. Health and Human Services Secretary Xavier Becerra has extended the COVID-19 public health emergency for another 90 days, through July 15. It was due to end on Saturday, April 16.
Major hospital groups and group purchasing organizations asked Becerra
…
Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
Astellas posted
A federal appeals court in Chicago has told a lower court in Indianapolis to issue a final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit to clear the way for the case’s next phase.
An appeals court in Philadelphia
…
Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the
…
Small rural hospitals have lost on average 39% of their 340B contract pharmacy savings due to drug manufacturers’ conditions on 340B pricing while larger, mostly urban hospitals have lost on average 23%, a hospital group’s member survey shows.
The finding
…